Cell Therapeutics (CTIC) Posts Q3 Loss of 16c/Share; Resubmits Pixantrone NDA to FDA
Tweet
Share
E-mailGet Alerts CTIC Hot Sheet
Price: $9.09 --0%
Revenue Growth %: -100.0%
Financial Fact:
Total revenues: 4.43M
Today's EPS Names:
NLY, CP, RUSHA, More
Revenue Growth %: -100.0%
Financial Fact:
Total revenues: 4.43M
Today's EPS Names:
NLY, CP, RUSHA, More
Join SI Premium – FREE
Cell Therapeutics Inc. (NASDAQ: CTIC) reported Q3 loss of ($0.16), $0.07 worse than the analyst estimate of ($0.09).
Cell Therapeutics also resubmitted the pixantrone NDA to the FDA for review to treat relapsed or refractory aggressive non-Hodgkin's lymphoma for patients who have failed two or more prior lines of therapy.
Cell Therapeutics also resubmitted the pixantrone NDA to the FDA for review to treat relapsed or refractory aggressive non-Hodgkin's lymphoma for patients who have failed two or more prior lines of therapy.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Plexus Corp (PLXS) Tops Q2 EPS by 7c
- Ford (F) earnings beat estimates in Q1, revenue falls short; stock up
- Core Laboratories (CLB) Misses Q1 EPS by 13c
Create E-mail Alert Related Categories
Commodities, Earnings, FDASign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
